Annovis Bio enters $50M at-the-market equity distribution agreement with Oppenheimer

Annovis Bio, Inc.

Agreement allows sale of up to $50M of common stock at-the-market through Oppenheimer & Co.
Oppenheimer will receive 3.0% commission on gross proceeds; company also reimburses certain expenses.
Company has no obligation to sell any shares and may suspend or terminate the agreement at any time.
Shares will be issued under existing effective shelf registration statement (File No. 333-276814).
Offering is effective December 11, 2024; sales subject to company instructions and market conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.